Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • Target Validation, 2015
    Targeting the NLRP3 Inflammasome in Models of Parkinson's Disease

    Objective/Rationale:             
    Chronic inflammation within the brain is emerging as a possible driver in the progression of Parkinson’s disease (PD). Inflammasomes are protein complexes that...

  • Research Grant, 2015
    VPAC2 Agonists Neuroprotective and Anti-inflammatory Effects in Parkinson's Disease

    Study Rationale:                   
    The adaptive and innate immune responses play intricate roles in modulating neuroinflammation and may be harnessed for neuroprotection from Parkinson’s disease. We...

  • Therapeutic Pipeline Program, 2015
    Improving Access to Depression Care in Parkinson’s Disease: A Telehealth Approach

    Study Rationale:                   
    There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson’s disease (PD)...

  • Biomarker Development, 2015
    Comparison of Pre- and Post-mortem Cerebrospinal Fluid Levels of Proteins and Lipids

    Study Rationale:                   
    Alpha-synuclein aggregation in the brain is the main pathology of Parkinson’s disease (PD). Cerebrospinal fluid (CSF) levels of alpha-synuclein are lower in PD. It...

  • Dyskinesia Challenge, 2015
    Biomarkers and Sensors for Levodopa-induced Dyskinesia

    Study Rationale:                   
    Levodopa is the gold-standard drug for treatment of Parkinson’s disease (PD), but chronic use is associated with serious motor complications called levodopa-induced...

  • Dyskinesia Challenge, 2015
    Targeting M4 Muscarinic Receptors for the Treatment of Levodopa-induced Dyskinesia

    Study Rationale:                   
    Levodopa-induced dyskinesia is thought to stem from sustained stimulation of D1 dopamine receptors (D1Rs). One potential strategy for diminishing excessive D1R...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.